Anika Therapeutics Inc. (ANIK) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 895,600 shares of the biotechnology company’s stock after acquiring an additional 17,594 shares during the period. Dimensional Fund Advisors LP owned about 6.11% of Anika Therapeutics worth $51,945,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of ANIK. SG Americas Securities LLC acquired a new position in shares of Anika Therapeutics in the third quarter worth $118,000. Victory Capital Management Inc. grew its stake in shares of Anika Therapeutics by 17.6% in the second quarter. Victory Capital Management Inc. now owns 4,060 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 608 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Anika Therapeutics by 3.0% in the second quarter. BNP Paribas Arbitrage SA now owns 4,315 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 126 shares in the last quarter. Stevens Capital Management LP acquired a new position in shares of Anika Therapeutics in the third quarter worth $222,000. Finally, Miles Capital Inc. acquired a new position in shares of Anika Therapeutics in the second quarter worth $232,000. Institutional investors and hedge funds own 84.91% of the company’s stock.

Anika Therapeutics Inc. (NASDAQ:ANIK) opened at $55.50 on Friday. The company has a market cap of $808.01, a price-to-earnings ratio of 26.06, a price-to-earnings-growth ratio of 3.34 and a beta of 1.44. Anika Therapeutics Inc. has a 12 month low of $41.64 and a 12 month high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.05. The business had revenue of $27.18 million during the quarter, compared to the consensus estimate of $27.44 million. Anika Therapeutics had a net margin of 28.23% and a return on equity of 13.40%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.59 earnings per share. research analysts forecast that Anika Therapeutics Inc. will post 1.9 earnings per share for the current fiscal year.

ANIK has been the subject of several research reports. Barrington Research boosted their price target on shares of Anika Therapeutics from $53.00 to $57.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. BidaskClub downgraded shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th.

In related news, insider Richard Hague sold 5,250 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $54.48, for a total transaction of $286,020.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Charles H. Sherwood sold 7,124 shares of the business’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $60.08, for a total transaction of $428,009.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,886 shares of company stock valued at $2,606,455. Insiders own 6.57% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3126550/anika-therapeutics-inc-anik-shares-bought-by-dimensional-fund-advisors-lp.html.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.